Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Chinese Medical Journal
|
April 14, 2023
Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
Wenjie Xiong, Tingyu Wang, Ying Yu, et al.
Blood Science (Baltimore, Md.)
|
January 19, 2024
Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
Ying Yu, Wenjie Xiong, Tingyu Wang, et al.
British Journal of Haematology
|
July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma
Rui Lyu, Tingyu Wang, Yi Wang, et al.
Haematologica
|
January 11, 2024
Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial
Wenjie Xiong, Rui Lyu, Ying Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Wenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Frontiers in Immunology
|
October 9, 2024
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways
Lanting Liu, Dasen Gong, Hao Sun, et al.
Chinese Medical Journal
|
January 17, 2017
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia
Heng Li, Shu-Hua Yi, Wen-Jie Xiong, et al.
Chinese Medical Journal
|
December 7, 2023
Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features
Hesong Zou, Wei Liu, Yi Wang, et al.
Nature Communications
|
October 14, 2023
Achieving health-oriented air pollution control requires integrating unequal toxicities of industrial particles
Di Wu, Haotian Zheng, Qing Li, et al.
Medscience
|
June 2, 2026
Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study
Yuting Yan, Xinyang Hu, Xiuhua Sun, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Chinese Medical Journal
|
April 14, 2023
Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
Wenjie Xiong, Tingyu Wang, Ying Yu, et al.
Blood Science (Baltimore, Md.)
|
January 19, 2024
Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
Ying Yu, Wenjie Xiong, Tingyu Wang, et al.
British Journal of Haematology
|
July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma
Rui Lyu, Tingyu Wang, Yi Wang, et al.
Haematologica
|
January 11, 2024
Rituximab plus cyclophosphamide and dexamethasone <i>versus</i> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial
Wenjie Xiong, Rui Lyu, Ying Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Wenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Frontiers in Immunology
|
October 9, 2024
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways
Lanting Liu, Dasen Gong, Hao Sun, et al.
Chinese Medical Journal
|
January 17, 2017
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia
Heng Li, Shu-Hua Yi, Wen-Jie Xiong, et al.
Chinese Medical Journal
|
December 7, 2023
Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features
Hesong Zou, Wei Liu, Yi Wang, et al.
Nature Communications
|
October 14, 2023
Achieving health-oriented air pollution control requires integrating unequal toxicities of industrial particles
Di Wu, Haotian Zheng, Qing Li, et al.
Medscience
|
June 2, 2026
Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study
Yuting Yan, Xinyang Hu, Xiuhua Sun, et al.
Page
of 7